MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma

Clin Cancer Res. 2011 Jul 15;17(14):4761-71. doi: 10.1158/1078-0432.CCR-11-0494. Epub 2011 May 24.

Abstract

Purpose: We investigated prognostic implications of microRNAs in extranodal NK/T cell lymphoma (NKTL).

Experimental design: We measured miRNA expression in NKTL tissues and cell lines, using real-time PCR, and analyzed its role in NKTL, using cell lines.

Results: Multivariate analysis showed low miR-146a expression (P < 0.001; HR = 13.110), primary non-upper aerodigestive tract lesion (non-UAT; P = 0.008; HR = 5.376) and high International Prognostic Index (IPI; ≥3; P = 0.013; HR = 3.584) to be independent poor prognostic factors. miR-146a expression could subdivide UAT-NKTL into 2 prognostic groups, resulting in the following prognostic groups: (i) UAT(Low-146a), (ii) UAT(High-146a), and (iii) non-UAT. Compared with UAT(High-146a), UAT(Low-146a) showed distinctively poor prognosis (P < 0.001; HR = 15.620), similar to the non-UAT group. In vitro, miR-146a overexpression in NKTL cell lines, SNK6 and YT, inhibited nuclear factor κB (NFκB) activity, suppressed cell proliferation, induced apoptosis, and enhanced chemosensitivity. TNF receptor-associated factor 6, a target of miR-146a and a known NFκB activator, was downregulated by miR-146a in SNK6 and YT cells. Promoter methylation of miR-146a gene was observed in SNK6 and YT cells, as well as in NKTL tissues with low miR-146a expression, and miR-146a expression was induced by the conversion of methylation status with a demethylating agent in SNK6 and YT cells.

Conclusions: These results suggest that miR-146a might function as a potent tumor suppressor in NKTL and be useful for patient assessment and therapeutic targeting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Child
  • DNA Methylation / genetics
  • DNA Modification Methylases / antagonists & inhibitors
  • Decitabine
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Drug Synergism
  • Etoposide / pharmacology
  • Etoposide / therapeutic use
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genes, Tumor Suppressor*
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Extranodal NK-T-Cell / diagnosis*
  • Lymphoma, Extranodal NK-T-Cell / drug therapy
  • Lymphoma, Extranodal NK-T-Cell / mortality
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Middle Aged
  • NF-kappaB-Inducing Kinase
  • Prognosis
  • Promoter Regions, Genetic
  • Protein Serine-Threonine Kinases / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • TNF Receptor-Associated Factor 6 / genetics
  • TNF Receptor-Associated Factor 6 / metabolism*
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • MIRN146 microRNA, human
  • MicroRNAs
  • TNF Receptor-Associated Factor 6
  • Etoposide
  • Decitabine
  • DNA Modification Methylases
  • Protein Serine-Threonine Kinases
  • Azacitidine